Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

Open Access Journal of Urology

Volumn 3, Issue 1, 2011, Pages 69-82

  Zustovich, Fable ^a   Lombardi, Giuseppe ^a   Pastorelli, Davide ^a   Farina, Patrizia ^a   dal Bianco, Massimo ^b   de Zorzi, Luca ^b   Palma, Maurizia Dalla ^a   Nicoletto, Ornella ^a   Zagonel, Vittorina ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b S ANTONIO HOSPITAL   (Italy)

Author keywords

Angiogenesis; Pharmacokinetics; Sorafenib

Indexed keywords

ANALGESIC AGENT; BEVACIZUMAB; CREATININE; DEXTROMETHORPHAN; DOXORUBICIN; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERFERON; KERATOLYTIC AGENT; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MIDAZOLAM; OMEPRAZOLE; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; SORAFENIB; STEROID; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN; WARFARIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLEEDING; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; COMORBIDITY; CONSTIPATION; CONTINUOUS INFUSION; CREATININE CLEARANCE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; HAND FOOT SYNDROME; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; IC 50; INTERNATIONAL NORMALIZED RATIO; KIDNEY CARCINOMA; LIVER DISEASE; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PRURITUS; QT INTERVAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN TOXICITY; SOCIAL SUPPORT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 79957807483     PISSN: None     EISSN: 11791551     Source Type: Journal    
DOI: 10.2147/OAJU.S7230     Document Type: Review

References (80)

1. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000;27(2):115-123.
2. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998;352(9141): 1691-1696.
3. Godley PA, Taylor M. Renal cell carcinoma. Curr Opin Oncol. 2001; 13(3):199-203.
4. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611-1623.
5. Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4(5):363-372.
6. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80(5):987-989.
7. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000; 27(2):177-186.
8. Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology. 2008;74(3-4): 245-246.
9. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;1:CD001425.
10. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am. 1997;3 Suppl 1:S79-S84.
11. Gitlitz BJ, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin Urol Oncol. 1996;14(4):237-243.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
13. Alavi A, Hood JD, Frausto R, et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003;301(5629): 94-96.
14. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577): 2404-2407.
15. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12(1):122-127.
16. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991-5004.
17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2): 125-134.
18. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.
19. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
20. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2781.
21. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled Phase III trial. Lancet. 2008;372(9637):449-456.
22. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144-2150.
23. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-2143.
24. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835-844.
25. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59(5):561-574.
26. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24(9): 1363-1369.
27. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223-240.
28. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazolemediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006;57(5):685-692.
29. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99(1): 159-165.
30. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293-4300.
31. Porta C, Bracarda S. Presente e futuro di sorafenib in oncologia - Ed Accademia Nazionale di Medicina. Genoa: Forum Service; 2011.
32. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11(15):5472-5480.
33. Strumberg D, Schultheis B, Adamietz IA, et al. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumors. Br J Cancer. 2008;99(10):1579-1585.
34. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27(11):1800-1805.
35. Strumberg D, Voliotis D, Moeller JG, et al. Results of Phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther. 2002;40(12):580-581.
36. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer. 2005;92(10): 1855-1861.
37. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505-2512.
38. Maroto-Rey P, Bellmunt J, Trigo JM et al. First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment. ASCO Annual Meeting Proceedings. J Clin Oncol, 2007; I(25)Supp18:15640.
39. Szczylik C, Demkow T, Staehler M, et al. Randomised phase II trial of firstline treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18):5025.
40. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318.
41. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26(28): 4572-4578.
42. Lamuraglia M, Escudier B, Chami L, et al. To predict progression- free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer. 2006;42(15):2472-2479.
43. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272-1280.
44. J Beck, G Procopio, U Keilholz, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expandedaccess study: a large open-label study in diverse community settings. Ann Oncol. February 15, 2011. [Epub ahead of print].
45. Nexavar FDA product information. http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Accessed March 1, 2011.
46. Hutson TE, Bellmunt J, Porta C, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from Phase III TARGET. Eur J Cancer. 2010;46(13):2432-2440.
47. Tolcher AW, Appleman LJ, Shapiro GI, et al. A Phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. June 3, 2010. [Epub ahead of print].
48. Parsa VK, Heilbrun L, Smith D, et al. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function [abstract 365]. Proceedings of the 2008 Genitourinary Cancers Symposium.
49. Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 2008;8(1):63-73.
50. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127-131.
51. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235-241.
52. Bellmunt J, Eisen T, Szczylik C, et al. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 2010 [Epub ahead of print].
53. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10(3):198-204.
54. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824-1831.
55. Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100(20):1454-1463.
56. Bukowski RM. Renal cell carcinoma: a model system for novel drug development? Clin Genitourin Cancer. 2008;6(1):7-8.
57. Porta C, Paglino C, Imarisio I, Ferraris E. Sorafenib tosylate in advanced kidney cancer: past, present and future. Anticancer Drugs. 2009;20(6):409-415.
58. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007;30(3): 220-227.
59. Beck J, Procopio G, Negrier S, et al. Final analysis of a large open- label, noncomparative study of sorafenib in European patients with advanced RCC (EU-ARCCS) [poster]. Presented at the 34th ESMO Annual Congress; September 20-24, 2009. Berlin, Germany.
60. Flaherty KT, Brose MS. Sorafenib-related hand-foot skin reaction improves, not worsens, with continued treatment. Clin Cancer Res. 2009;15(24):7749.
61. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008; 13(9):1001-1011.
62. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955-1961.
63. Nexavar EMA product information: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf. Accessed March 1, 2011.
64. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48(7):964-970.
65. Halbert RJ, Figlin RA, Atkins MB, et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer. 2006;107(10):2375-2383.
66. National Comprehensive Cancer Network. NCCN guidelines for renal cell carcinoma. V 2.2011 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 1, 2011.
67. Bellmunt J, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010;10(6):825-835.
68. Escudier B, Szczylik C, Hutson TE, et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon a-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2001;27(8):1280-1289.
69. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a Phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25(22): 3296-3301.
70. Jonasch E, Corn P, Pagliaro LC, et al. Upfront, randomized, Phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010;116(1):57-65.
71. Garcia JA, Hutson TE, Elson P, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116(23):5383-5390.
72. Kontovinis L, Laschos K, Karadimou A, et al. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol. January 30, 2011. [Epub ahead of print].
73. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179(1):81-86; discussion 86.
74. Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expandedaccess study: a large open-label study in diverse community settings. Ann Oncol. February 15, 2011. [Epub ahead of print].
75. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182(1):29-34; discussion 34.
76. Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115(1):61-67.
77. De Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009;45(5): 765-773.
78. Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. European J Clin Med Oncol. December 21, 2010. [Epub ahead of print].
79. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
80. Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76(2): 430-434.